Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Antidysrhythmic Toxicity Treatment & Management

  • Author: Nidhish Sasi, MD; Chief Editor: Asim Tarabar, MD  more...
 
Updated: Jun 27, 2016
 

Approach Considerations

Airway, breathing, and circulatory support (ABCs); intravenous (IV) access; and electrocardiographic (ECG) monitoring are of paramount importance. Emergency medicine physicians should arrange with cardiology or toxicology service for admission of the patient to a monitored bed in cardiac unit.

Consult with a medical toxicologist and/or a regional poison control center for acute toxicity. Consult with a cardiologist for long-term plans or to continue intensive monitoring in a cardiac unit.

Treatment measures and the drugs for which they are appropriate are as follows (for more details on each agent, refer to each individual section).

Next

Disopyramide

Sodium bicarbonate is indicated for patients with a widened QRS complex. Closely monitor for resultant alkalemia, hypokalemia, and hypomagnesemia. Because disopyramide blocks calcium channels, administration of calcium may help treat hypotension. Patient with disopyramide-induced symptoms of overt heart failure may benefit from diuretics, inotropic agents, or afterload-reducing drugs. IV magnesium sulfate may be used to treat QT prolongation and torsades de pointes. [38]

GI decontamination is sometimes warranted to decrease GI disopyramide absorption, because of its anticholinergic effects. Hemodialysis is effective in decreasing the serum half-life and may be useful as second-line therapy when supportive care is not effective.[39, 40]

 

 

Previous
Next

Procainamide

Implement supportive care. Orogastric lavage and activated charcoal should be considered for oral overdoses. If renal failure is present, consider hemodialysis, although its value in this setting has not yet been confirmed. Avoid other QT interval–prolonging agents. Avoid the class IA antidysrhythmics quinidine and disopyramide, due to prodysrhythmic and QT interval–prolonging effects. Consider early pacemaker placement in patients with increasing atrioventricular block. Ventricular tachycardia or fibrillation in the setting of Brugada syndrome is best managed with isoproterenol rather than amiodarone. Mechanical ventilation may be required for acute but rare respiratory compromise due to myasthenia gravis–like syndrome or myositis.

 

 

Previous
Next

Quinidine

In the setting of acute cardiotoxicity with QRS interval widening, hypertonic sodium bicarbonate is indicated. Symptomatic bradycardia may require placement of a temporary pacemaker. In patients with hypotension, blood pressure should be supported with normal saline and vasopressors. Dysrhythmias may be treated with a class IB agent.

After intravenous access, oxygen, and cardiac monitoring are initiated, seizures should be treated with benzodiazepines. Check serum glucose and electrolyte levels such as calcium if seizures are not responsive.

Orogastric lavage and activated charcoal shoudl be considered for gastrointestinal decontamination. 

Correct imbalances of electrolytes (eg, potassium, calcium) and glucose. Due to its very large volume of distribution, quinidine is not amenable to dialysis. Experience with charcoal hemoperfusion is limited. Glucagon has been proven useful in animal models but such data are lacking in humans.

Previous
Next

Lidocaine

Benzodiazepines are the first-line treatment for seizures due to lidocaine overdose. Providers should avoid phenytoin, which is another 1B sodium-channel blocker and could worsen toxicity.  

Phenobarbital, propofol, and thiopental have also been reported to succesfully treat local anesthetic lidocaine–induced CNS toxicity, including seizures and muscle twitching.

In benzodiazepine-refractory seizures, providers should escalate care with propofol or a barbiturate, a neuromuscular antagonist, and endotracheal intubation, because acidosis will potentiate lidocaine toxicity. For severe acidosis, treat with sodium bicarbonate.

Intravenous infusion of lipid emulsions should be considered for severe toxicity.

Cardiopulmonary bypass has been used to treat cardiac arrest secondary to lidocaine toxicity. Amiodarone is the recommended agent to treat defibrillation. Avoid other class IB antiarrhythmics, as well as class II and class IV agents, during lidocaine-induced cardiac arrest.[41, 42]

Previous
Next

Mexiletine

No specific antidotes are available for mexiletine. Active charcoal after recent ingestion may be appropriate. A portion of ingested mexiletine is bound to low molecular weight plasma proteins, and hemodialysis has been shown to be associated with improvement in vital signs when supportive care with intravenous fluids and vasopressors has failed.[43]

Previous
Next

Flecainide

Intravenous sodium bicarbonate, 100 mEq over 5 minutes, followed by continuous infusion to maintain a serum pH of 7.5-7.55, has reversed hypotension and resulted in significant narrowing of the QRS complex. Urine alkalinization may reduce renal clearance; hypertonic sodium chloride might theoretically provide a better therapeutic effect. Hyponatremia should be corrected. 

Intravenous fat emulsion has been shown to treat life-threatening flecainide overdose in case reports.[44]

Cardiopulmonary bypass and extracorporeal membrane oxygenation have been reported and may be reasonable if available in cases of severe toxicity refractory to supportive measures.[45]

Electrolyte management is crucial in flecainade toxicity because hyponatremia can increase toxicity. [46, 47]

Previous
Next

Propafenone

Sodium bicarbonate is recommended for cardiotoxicity with a widened QRS complex, as it has been shown to narrow QRS complexes. Glucagon may be indicated for excessive beta blockade effect such as bradycardia. 

Supportive treatment with intravenous fluids and inotropic and vasopressor support is indicated for hypotensive patients. Temporary pacing for bradycardia was effective for improving hemodynamics in a case report.[48]  

Gastric lavage is useful in patients with severe recent toxic ingestions.[49]

 

Previous
Next

Amiodarone

Multiple-dose activated charcoal may be helpful following overdose. If bradycardia occurs, use a pacemaker or beta-adrenergic agonist. In cases of acute pulmonary toxicity, oral steroids may help. Intubation and supportive care are necessary if severe pulmonary toxicty or an acute respiratory distress (ARDS) presentation occurs. 

Amiodarone and its metabolite are not dialyzable. Given its long half-life (25-100 days), toxicity may continue despite cessation of treatment.

Previous
Next

Dronedarone

Treatment is supportive. Heart failure may be treated with inotropes and diuretics.  Pulmonary toxicity such as pneumonitis or organizing pneumonia may respond to steroids and not antibiotics. Rare fulminant hepatic failure may necessitate liver transplantation. Whether dronedarone and its metabolites can be removed by dialysis remains unknown. 

Previous
Next

Sotalol

Treatment is supportive and symptomatic. Hemodialysis is helpful in reducing plasma concentrations. See Torsade de Pointes Treatment, below.

Previous
Next

Ibutilide

Prophylactic administration of magnesium in high doses may increase the safety and efficacy of ibutilide in converting atrial fibrillation. Supportive and resuscitative measures should be available for cardiac arrest from ventricular dysrhythymia due to ibutilide.[50]

Previous
Next

Dofetilide

Activated charcoal should be considered after a recent ingestion. Consider repletion of potassium and magnesium and supplementation of magnesium. See Torsades de Pointes Treatment, below.

 

Previous
Next

Adenosine

External pacing pads should be available during adenosine administration. The short half-life of adenosine limits the duration of adverse effects in most cases.  

Previous
Next

Torsade de Pointes Treatment

Torsades de pointes generally occurs immediately after drug therapy has begun; drug infusion should immediately be stopped. Magnesium in a 2-g bolus should be administered. Overdrive pacing and isoproterenol should also be considered as therapeutic actions if torsade de pointes persists.

Previous
Next

Lipid Emulsion Therapy

Intravenous lipid emulsion (ILE) therapy has demonstrated efficacy as a life-saving antidote for cardiotoxicity from local anesthetics, with the best evidence for bupivicaine toxicity.[33] Postulated mechanisms of action include the creation of a lipid compartment that takes unbound, lipophilic drugs out of the plasma, improving the delivery of energy substrates to myocardial mitochondria, and increasing the intracellular myocyte calcium concentration (thereby augmenting inotropy).

There is some evidence of ILE efficacy for beta-blocker[51] and calcium channel blocker overdose.[52, 53] Flecainide overdose has also been treated successfully with ILE.[44] This approach may be considered for amiodarone overdose, given that drug's high degree of lipophilicity and partitioning into the lipid emulsion compartment.[54]

The recommended dose for local anesthetic toxicity (unlabeled use) is a bolus of 20% intralipid/fat emulsion at 1.5 mg/kg administered over 1 minute, followed by an infusion of 0.25 mL/kg/minute. The bolus dose can repeated 1-2 times, and the infusion rate can be increased to 0.5 mL/kg/minute. Infusion should be continued for 10 minutes after hemodynamic stability is restored.

Previous
 
 
Contributor Information and Disclosures
Author

Nidhish Sasi, MD Resident Physician, Department of Emergency Medicine, Kings County Hospital Center, State University of New York Downstate Medical Center

Nidhish Sasi, MD is a member of the following medical societies: American Medical Association, American College of Emergency Physicians

Disclosure: Nothing to disclose.

Coauthor(s)

Sage W Wiener, MD Assistant Professor, Department of Emergency Medicine, State University of New York Downstate Medical Center; Director of Medical Toxicology, Department of Emergency Medicine, Kings County Hospital Center

Sage W Wiener, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Jennifer L Martindale, MD Clinical Assistant Professor, Department of Emergency Medicine, Kings County Hospital, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Denise Ammon, MD, MA Resident Physician, Department of Emergency Medicine, Kings County Hospital, State University of New York Downstate Medical Center

Denise Ammon, MD, MA is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, American Medical Student Association/Foundation, American Society of Anesthesiologists, Emergency Medicine Residents' Association

Disclosure: Nothing to disclose.

Acknowledgements

Michael J Burns, MD Instructor, Department of Emergency Medicine, Harvard University Medical School, Beth Israel Deaconess Medical Center

Michael J Burns, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Miguel C Fernandez, MD, FAAEM, FACEP, FACMT, FACCT Associate Clinical Professor, Department of Surgery/Emergency Medicine and Toxicology, University of Texas School of Medicine at San Antonio; Medical and Managing Director, South Texas Poison Center

Miguel C Fernandez, MD, FAAEM, FACEP, FACMT, FACCT is a member of the following medical societies: American Academy of Emergency Medicine, American College of Clinical Toxicologists, American College of Emergency Physicians, American College of Medical Toxicology, American College of Occupational and Environmental Medicine, Society for Academic Emergency Medicine, and Texas Medical Association

Disclosure: Nothing to disclose.

Joshua B Gaither, MD Fellow in Emergency Medicine Services, Prehospital and Disaster Care, Denver Health-University of Colorado

Joshua B Gaither, MD is a member of the following medical societies: American College of Emergency Physicians, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Eileen C Quintana, MD Assistant Professor, Departments of Pediatrics and Emergency Medicine, St Christopher's Hospital for Children; Adjunct Clinical Professor, Departments of Pediatrics and Emergency Medicine, Temple University Hospital

Eileen C Quintana, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Richard H Sinert, DO Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Carin M Van Gelder, MD Assistant Professor, Department of Emergency Medicine, Yale University School of Medicine; EMS Medical Director, NHSHP and EMS Physician, SHARP Team; Attending Physician, Emergency Medicine, Yale-New Haven Medical Center

Carin M Van Gelder, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Massachusetts Medical Society, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

References
  1. Duncan WJ, Tyrrell MJ, Bharadwaj BB. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can J Cardiol. 1991 Mar. 7 (2):81-6. [Medline].

  2. Atkinson AJ Jr, Krumlovsky FA, Huang CM, del Greco F. Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. Clin Pharmacol Ther. 1976 Nov. 20(5):585-92. [Medline].

  3. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol. 2004 Jun. 27 (6 Pt 1):821-3. [Medline].

  4. Collinsworth KA, Kalman SM, Harrison DC. The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation. 1974 Dec. 50 (6):1217-30. [Medline].

  5. Napolitano C, Bloise R, Priori SG. Gene-specific therapy for inherited arrhythmogenic diseases. Pharmacol Ther. 2006 Apr. 110 (1):1-13. [Medline].

  6. Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, et al. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. Clin Pharmacol Ther. 2001 Mar. 69 (3):104-7. [Medline].

  7. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21. 324 (12):781-8. [Medline].

  8. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 2000 Aug 29. 102 (9):945-7. [Medline].

  9. Siu CW, Wong MP, Ho CM, Lam CL, Tse HF. Fatal lung toxic effects related to dronedarone use. Arch Intern Med. 2012 Mar 26. 172 (6):516-7. [Medline].

  10. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007 Dec. 64 (6):785-91. [Medline].

  11. Saarimaa H. Combination of clonidine and sotalol in hypertension. Br Med J. 1976 Apr 3. 1 (6013):810. [Medline].

  12. Frick M, Darpö B, Ostergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J. 2000 Jul. 21 (14):1177-85. [Medline].

  13. Somberg JC, Preston RA, Ranade V, Cvetanovic I, Molnar J. Gender differences in cardiac repolarization following intravenous sotalol administration. J Cardiovasc Pharmacol Ther. 2012 Mar. 17(1):86-92. [Medline].

  14. Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med. 2011 Jan-Feb. 24 (1):86-92. [Medline].

  15. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000 Nov 7. 102 (19):2385-90. [Medline].

  16. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol (Phila). 2015. 53 (10):962-1147. [Medline]. [Full Text].

  17. Zitnik, RJSO. Drug-induced lung disease: Antiarrhythmic agents. J Respir Dis. 1996. 17:254.

  18. Venkayya RV, Poole RM, Pentz WH. Respiratory failure from procainamide-induced myopathy. Ann Intern Med. 1993 Aug 15. 119 (4):345-6. [Medline].

  19. Godley PJ, Morton TA, Karboski JA, Tami JA. Procainamide-induced myasthenic crisis. Ther Drug Monit. 1990 Jul. 12 (4):411-4. [Medline].

  20. Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis. 1977 Sep-Oct. 20 (2):151-63. [Medline].

  21. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000 Sep. 93 (9):457-62. [Medline].

  22. Somberg JC, Timar S, Bailin SJ, Lakatos F, Haffajee CI, Tarjan J, et al. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004 Mar 1. 93 (5):576-81. [Medline].

  23. Lindquist DE, Rowe AS, Heidel E, Fleming T, Yates JR. Evaluation of the Hemodynamic Effects of Intravenous Amiodarone Formulations During the Maintenance Phase Infusion. Ann Pharmacother. 2015 Dec. 49 (12):1317-21. [Medline].

  24. Nacca N, Bhamidipati CM, Yuhico LS, Pinnamaneni S, Szombathy T. Severe amiodarone induced pulmonary toxicity. J Thorac Dis. 2012 Dec. 4 (6):667-70. [Medline].

  25. Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol. 2008 Jul. 66 (1):82-7. [Medline].

  26. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997 Sep. 30 (3):791-8. [Medline].

  27. Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol. 2009 Jul. 66 (7):865-9. [Medline].

  28. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008 Jun 19. 358(25):2678-87. [Medline].

  29. Danielly J, DeJong R, Radke-Mitchell LC, Uprichard AC. Procainamide-associated blood dyscrasias. Am J Cardiol. 1994 Dec 1. 74 (11):1179-80. [Medline].

  30. Hudson CJ, Whitner TE, Rinaldi MJ, Littmann L. Brugada electrocardiographic pattern elicited by inadvertent flecainide overdose. Pacing Clin Electrophysiol. 2004 Sep. 27(9):1311-3. [Medline].

  31. Thevenin J, Da Costa A, Roche F, Romeyer C, Messier M, Isaaz K. Flecainide induced ventricular tachycardia (torsades de pointes). Pacing Clin Electrophysiol. 2003 Sep. 26 (9):1907-8. [Medline].

  32. Odeh M, Seligmann H, Oliven A. Propafenone-induced ataxia: report of three cases. Am J Med Sci. 2000 Aug. 320 (2):151-3. [Medline].

  33. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 1993 Aug 12. 72(4):44A-50A. [Medline].

  34. Merola JF. Lupus-like syndromes related to drugs. Schur PH, Massarotti E. Lupus Erythematosus: Clinical Evaluation and Treatment. New York: Springer; 211-221.

  35. [Guideline] Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000 Jun 26. 160 (12):1741-8. [Medline].

  36. Richer M, Robert S. Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother. 1995 Jun. 29 (6):582-6. [Medline].

  37. Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade de pointes: the clinical considerations. Int J Cardiol. 2004 Jul. 96 (1):1-6. [Medline].

  38. Tzivoni D, Keren A, Stern S, Gottlieb S. Disopyramide-induced Torsade de Pointes. Arch Intern Med. 1981 Jun. 141 (7):946-7. [Medline].

  39. Arimori K, Kawano H, Nakano M. Gastrointestinal dialysis of disopyramide in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1989 Jun. 27 (6):280-4. [Medline].

  40. Holt DW, Helliwell M, O'Keeffe B, Hayler AM, Marshall CB, Cook G. Successful management of serious disopyramide poisoning. Postgrad Med J. 1980 Apr. 56 (654):256-60. [Medline].

  41. Neal JM, Mulroy MF, Weinberg GL, American Society of Regional Anesthesia and Pain Medicine. American Society of Regional Anesthesia and Pain Medicine checklist for managing local anesthetic systemic toxicity: 2012 version. Reg Anesth Pain Med. 2012 Jan-Feb. 37 (1):16-8. [Medline].

  42. Mazoit JX, Le Guen R, Beloeil H, Benhamou D. Binding of long-lasting local anesthetics to lipid emulsions. Anesthesiology. Feb 2009. 110(2):380-6. [Medline].

  43. Akinci E, Yüzbasioglu Y, Coskun F. Hemodialysis as an alternative treatment of mexiletine intoxication. Am J Emerg Med. 2011 Nov. 29(9):1235.e5-6. [Medline].

  44. Ellsworth H, Stellpflug SJ, Cole JB, Dolan JA, Harris CR. A life-threatening flecainide overdose treated with intravenous fat emulsion. Pacing Clin Electrophysiol. 2013 Mar. 36(3):e87-9. [Medline].

  45. Auzinger GM, Scheinkestel CD. Successful extracorporeal life support in a case of severe flecainide intoxication. Crit Care Med. 2001 Apr. 29(4):887-90. [Medline].

  46. Qamar S, Hassan W, Sra J, Akhtar M, Mortada ME. Abstract 14890: Hyponatremia Associated with Flecainide: Case Series. Circulation. 2012. 126.21:[Full Text].

  47. Khavandi A, Walker. Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics. Emerg Med J. 2007. 24(5):[Medline].

  48. Wozakowska-Kaplon B, Stepien-Walek A. Propafenone overdose: cardiac arrest and full recovery. Cardiol J. 2010. 17(6):619-22. [Medline].

  49. Ovaska H, Ludman A, Spencer EP, Wood DM, Jones AL, Dargan PI. Propafenone poisoning--a case report with plasma propafenone concentrations. J Med Toxicol. 2010 Mar. 6 (1):37-40. [Medline].

  50. Patsilinakos S, Christou A, Kafkas N, Nikolaou N, Antonatos D, Katsanos S, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol. 2010 Sep 1. 106 (5):673-6. [Medline].

  51. Jovic-Stosic J, Gligic B, Putic V, Brajkovic G, Spasic R. Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. Clin Toxicol (Phila). 2011 Jun. 49(5):426-30. [Medline].

  52. Montiel V, Gougnard T, Hantson P. Diltiazem poisoning treated with hyperinsulinemic euglycemia therapy and intravenous lipid emulsion. Eur J Emerg Med. 2011 Apr. 18(2):121-3. [Medline].

  53. French D, Armenian P, Ruan W, Wong A, Drasner K, Olson KR, et al. Serum verapamil concentrations before and after Intralipid® therapy during treatment of an overdose. Clin Toxicol (Phila). 2011 Apr. 49(4):340-4. [Medline].

  54. French D, Smollin C, Ruan W, Wong A, Drasner K, Wu AH. Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicological emergencies. Clin Toxicol (Phila). 2011 Nov. 49(9):801-9. [Medline].

  55. Martindale JL, Brown DFM. Rapid Interpretation of ECGs in Emergency Medicine: A Visual Guide. Lippincott Williams and Wilkins; 2012.

  56. EM Williams. Classifying antiarrhythmic actions: by facts or speculation. The Journal of Clinical Pharmacology. 1992 Nov. 32:964–77. [Medline].

  57. Lim YP, Lin CL, Lin YN, Ma WC, Chen WC, Hung DZ, et al. Antiarrhythmic agents and the risk of malignant neoplasm of liver and intrahepatic bile ducts. PLoS One. 2015. 10 (1):e0116960. [Medline].

  58. Benowitz NL. Antiarrhythmic Drugs. Olson KR. Poisoning & Drug Overdose. 6th. Mcgraw-Hill; 2012.

  59. Piña IL, Oghlakian G. Adverse Cardiovascular Drug Interactions and Complications. Fuster V, Walsh RA, Harrington RA. Hurst's The Heart. 13th. Mcgraw-Hill; 2011.

  60. Benowitz NL. Quinidine and Other Type Ia Antiarrhythmic Drugs. Olson KR. Poisoning & Drug Overdose. 6th ed. McGraw-Hill; 2012.

  61. Trevor AJ, Katzung BG, Kruidering-Hall. Antiarrhythmic Drugs. Trevor AJ, Katzung BG, Kruidering-Hall. Katzung & Trevor's Pharmacology: Examination & Board Review,. 11th ed. McGraw-Hill; 2015.

  62. Frishman WH, Alwarshetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet. 2002. 41 (7):505-16. [Medline].

  63. Ting SM, Lee D, Maclean D, Sheerin NS. Paranoid psychosis and myoclonus: flecainide toxicity in renal failure. Cardiology. 2008. 111 (2):83-6. [Medline].

  64. Gentzkow GD, Sullivan JY. Extracardiac adverse effects of flecainide. Am J Cardiol. 1984 Feb 27. 53 (5):101B-105B. [Medline].

  65. Tsuchishita Y, Fukumoto K, Kusumoto M, Ueno K. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide. Biol Pharm Bull. 2008 Jul. 31 (7):1368-70. [Medline].

 
Previous
Next
 
ECG in a patient who ingested 4 of flecainide. QRS = 200 milliseconds; QTc = 585 milliseconds. Used with permission from Lippincott, Williams & Wilkins (in Martindale JL, Brown DFM. Rapid Interpretation of ECGs in Emergency Medicine: A Visual Guide. Lippincott Williams and Wilkins; 2012).
Schematic of the cardiac action potential. Phase 0 depicts the the influx of sodium ions. Phases 1 and 3 correspond to the sodium-channel inactivation and the repolarizing eflux of potassium ions, respectively. Phase 2 depicts the opening of voltage-sensitive calcium channels causing a plateau in voltage.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.